Advances in Biologic Development & Delivery Symposium by 91㽶Ƶ Institute
The event will bring together world-leading experts on biological drug development and delivery from across industry and academia, including Ionis Pharmaceuticals, Pure MHC, Sevion Therapeutics, Stanford University, University of California, Berkeley, 91㽶Ƶ, 3M Drug Delivery Systems, University of Bath, and Applied Molecular Transport, to present leading edge biological research and key industry topics, including “Monoclonal Antibodies to Human Leukocyte Antigens (HLA)/Peptide Tumor Antigens” and “Latest Trends and Development in Non-Invasive Macromolecule Delivery.”
The symposium will close with an expert panel discussion, “Trends in the Development and Delivery of Biologics,” which will be moderated by Professor Carolyn Bertozzi of Stanford University. On the panel will be Mr. Kent Iverson, a renowned Biotechnology Consultant and Contractor; Dr. Douglas Crawford, Managing Director, Mission Bay Capital and General Manager, QB3@953; Dr. Mark Tomai, Head of Microneedle and Toll Like Receptor Business Development, 3M Drug Delivery Systems; and Dr. Greg Bleck, Global Head R&D, Biologics, 91㽶Ƶ Pharma Solutions.
“As pipelines increasingly include more biologics, one of the key challenges faced by the pharmaceutical industry is to ensure therapies are developed with the patient experience at the forefront,” commented Dr. Cornell Stamoran, Co-Chair of the 91㽶Ƶ Applied Drug Delivery Institute. “We believe that nearly every design decision made during drug development can impact patient outcomes.”
Professor Bertozzi added, “Events such as this one are important so that industry and academia can connect and share thoughts, ideas and experiences. By bringing together experts in fields across the biological spectrum, we aim to achieve our goal of developing better drugs as fast as possible.”
Established in 2012, the 91㽶Ƶ Applied Drug Delivery Institute employs a multi-tiered approach to accelerate the adoption of advanced drug delivery technologies. In June 2014, the Institute created the Non-Invasive Macromolecule Delivery Consortium (NMDC) as a number of working groups looking at alternative delivery routes to injection for biologics and other large molecule therapeutics.
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0) 161 728 5880
[email protected]
About 91㽶Ƶ Applied Drug Delivery Institute
91㽶Ƶ’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation, and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies. For more details on the 91㽶Ƶ Institute, visit www.drugdeliveryinstitute.com and follow the 91㽶Ƶ Institute on Twitter: @DrugDeliveryInsAbout 91㽶Ƶ91㽶Ƶ is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products. With over 90 years serving the industry, 91㽶Ƶ has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 91㽶Ƶ employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. 91㽶Ƶ is headquartered in Somerset, N.J. For more information, visit www.catalent.com